Phuong Nguyen
Family · Westminster, CANPI 1811583073
Payments from drug & device makers
Across 107 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aimmune Therapeutics, Inc.$411
- Xeris Pharmaceuticals, Inc.$314
- Dexcom, Inc.$303
- AbbVie$281
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$219
- Novo Nordisk$207
- plus $746 from 16 others
What the payments were for
- Food & beverage$2,481100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aimmune Therapeutics, Inc. | 17 | $411 |
| Xeris Pharmaceuticals, Inc. | 4 | $314 |
| Dexcom, Inc. | 11 | $303 |
| AbbVie | 19 | $281 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 11 | $219 |
| Novo Nordisk | 14 | $207 |
| Madrigal Pharmaceuticals | 1 | $143 |
| Vanda Pharmaceuticals Inc. | 4 | $89 |
| Astellas Pharma US Inc | 3 | $70 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $65 |
| GSK | 3 | $59 |
| Eisai Inc. | 2 | $42 |
| Johnson & Johnson | 2 | $41 |
| Merck | 2 | $37 |
| Paratek Pharmaceuticals, Inc. | 2 | $36 |
| Bayer | 2 | $30 |
| Amarin Pharma, Inc. | 1 | $25 |
| Boston Scientific | 1 | $25 |
| Boehringer Ingelheim | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| AstraZeneca | 1 | $19 |
| Fidia Pharma USA Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GVOKE HYPOPEN$269
- REZDIFFRA$143
- DEXCOM G6 TRANSMITTER$101
How this compares
$2,481 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 35 | $29,085 |
| FarxigaDapagliflozin Propanediol | 19 | $24,729 |
| JardianceEmpagliflozin | 19 | $17,494 |
| VascepaIcosapent Ethyl | 19 | $8,918 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $8,290 |
| LinzessLinaclotide | 12 | $7,368 |
| Diclofenac Sodium | 24 | $1,903 |
| Icosapent Ethyl | 12 | $1,799 |
| Atorvastatin Calcium | 170 | $1,684 |
| Felodipine ErFelodipine | 30 | $962 |
| Rosuvastatin Calcium | 81 | $863 |
| Metoprolol Succinate | 54 | $823 |
| Metformin Hcl | 113 | $727 |
| Amlodipine Besylate | 163 | $693 |
| Losartan Potassium | 102 | $677 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $37 | $29,08535 claims |
| AstraZenecaFarxiga | $19 | $24,72919 claims |
| Boehringer IngelheimJardiance | $24 | $17,49419 claims |
| GSKTrelegy Ellipta | $59 | $8,29014 claims |
| AbbVieLinzess | $281 | $7,36812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,634 family providers in California.
Other family in Westminster
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.